More flexibility for EU drug trial harmonization scheme
This article was originally published in SRA
Drug companies conducting clinical trials in the EU using the voluntary harmonization procedure (VHP) can now increase the number of member states in which the trial is being conducted. To do so, they must ask the scheme co-ordinator, the Heads of Medicines Agencies, to carry out a "second round" of evaluation. Companies will need to ensure, however, that the number of additional member states requested does not exceed the number of member states in the initial VHP1.
You may also be interested in...
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Thirty-eight guidance documents have been posted on the tracker since its last update.
New treatments for advanced endometrial cancer and hereditary angioedema are among six drugs that have just been recommended for EU-wide approval. Harmonized EU advice has also been issued in relation to an investigational antibody combination for treating COVID-19.
As part of its big data initiative, the European Medicines Agency is supporting projects that will help identify appropriate real-world data sources for regulatory decision making.